A significant inflow of foreign investment into Uzbekistan'spharmaceutical industry has followed the August 1996 government decree on support for the sector. This has now allowed the state pharmaceutical enterprise Uzfarmprom to launch 10 concurrent projects, with investment ranging from $2.5 million to $12 million.
The Tashkent chemical and pharmaceutical facility is to be re-tooled to manufacture cold and flu medicines and polyvitamins, commencing February 1998. Bayer AG of Germany will provide up to $4.1 million in support.
The largest project is the construction of an infusion solutions factory in Karshi for the revived Uzitalmed joint venture company. This $20 million project was originally agreed by Zafarinvest and Kasio of Italy as a joint venture in 1995, but was put on ice because of funding problems and red tape. The agreement has now been revived, and a revised project envisages a plant to produce 15 million vials a year. The project may allow the country to offset up to a quarter of its drugs and medicines imports.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze